Beta Amyloid

Beta Amyloid製品

• All (33)
• Beta Amyloid阻害剤 (20)
• Beta Amyloid抗体(9)
• 新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S2215	DAPT	DAPT (GSI-IX、LY-374973) は新規の γ-セクレターゼ 阻害剤であり、HEK 293 細胞で 20 nM の IC50 で Aβ 産生を阻害します。 DAPT はヒト舌癌細胞のアポトーシス(apoptosis) を促進し、オートファジー (autophagy) を調節します。	Nat Biotechnol, 2024, 10.1038/s41587-024-02386-x Nat Commun, 2024, 15(1):9529 J Clin Invest, 2024, 134(18)e179860
S1575	RO4929097	RO4929097 (RG-4733) is a γ secretase inhibitor with IC50 of 4 nM in a cell-free assay, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively. Phase 2.	J Cell Physiol, 2024, 10.1002/jcp.31291 Cell Transplant, 2024, 33:9636897241288932 Res Sq, 2024, rs.3.rs-3843028
S5742	Deferoxamine mesylate	Deferoxamine mesylate is the mesylate salt of Deferoxamine, which forms iron complexes and is used as a chelating agent. Deferoxamine is a ferroptosis inhibitor that stabilizes HIF-1α expression and improves HIF-1α transactivity in hypoxic and hyperglycemic states in vitro. Deferoxamine decreases beta-amyloid (Aβ) deposition and induces autophagy.Please do not prepare stock solutions with normal saline or PBS, as precipitation may occur.	Mol Cancer, 2024, 23(1):240 Cancer Commun (Lond), 2024, 10.1002/cac2.12608 Adv Sci (Weinh), 2024, 11(40):e2402671
S8185	FPS-ZM1	FPS-ZM1 is a blood-brain-barrier permeant, non-toxic, tertiary amide compound which is a high affinity RAGE-specific inhibitor, blocking Aβ binding to the V domain of RAGE.	Clin Immunol, 2024, 262:110178 Pharmacol Res, 2023, 192:106791 Cell Death Dis, 2023, 14(12):825
S1262	Avagacestat (BMS-708163)	Avagacestat (BMS-708163) is a potent, selective, orally bioavailable γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 of 0.3 nM and 0.27 nM, demonstrating a 193-fold selectivity against Notch. Phase 2.	Nat Commun, 2022, 13(1):6345 Sci Rep, 2022, 12(1):7 Cell, 2021, 184(2):521-533.e14
S2660	MK-0752	MK-0752 is a moderately potent γ-secretase inhibitor, which reduces Aβ40 production with IC50 of 5 nM. Phase 1/2.	Nat Cell Biol, 2024, 26(3):353-365 Cancers (Basel), 2023, 15(6)1883 J Cancer Res Clin Oncol, 2023, 149(16):14691-14699
S1594	Semagacestat (LY450139)	Semagacestat (LY450139) is a γ-secretase blocker for Aβ42, Aβ40 and Aβ38 with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, also inhibits Notch signaling with IC50 of 14.1 nM in H4 human glioma cell. Phase 3.	Cancers (Basel), 2023, 15(6)1883 Sci Rep, 2022, 12(1):7 Calcif Tissue Int, 2022, 111(2):211-223
S1528	LY2811376	LY2811376 is the first orally available non-peptidic β-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM, that act to decrease Aβ secretion with EC50 of 300 nM, demonstrated to have 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including cathepsin D, pepsin, or renin. Phase 1.	Glycobiology, 2023, 33(4):325-341 J Agric Food Chem, 2022, 70(5):1536-1546 Sci Rep, 2022, 12(1):7
S4261	EUK 134	EUK 134, a synthetic superoxide dismutase (SOD)/catalase mimetic, exhibits potent antioxidant activities, and inhibits the formation of β-amyloid and related amyloid fibril.	Front Aging Neurosci, 2022, 14:1013943 Chem Biol Interact, 2021, 351:109756 Nat Commun, 2020, 23;11(1):433
S9664	Colivelin	Colivelin (CLN) is a brain-penetrant neuroprotective peptide with potent long-term capacity against Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. Colivelin is an activator of STAT3.	Commun Biol, 2024, 7(1):999 Heliyon, 2024, 10(9):e30445 Research Square, 2024, 10.21203/rs.3.rs-3840462/v1
S3922	(-)-epigallocatechin	(-)-Epigallocatechin, widespread in plants, has been shown to exhibit anti-tumor, anti-cancer and anti-inflammatory functions.	J Inflamm Res, 2023, 16:2007-2020 Eur J Pharmacol, 2020, 173323 Biochim Biophys Acta Biomembr, 2020, 1863(1):183476
S4760	(2-Hydroxypropyl)-β-cyclodextrin (HP-β-CD)	(2-Hydroxypropyl)-β-cyclodextrin (HP-β-CD, HP-β-cyclodextrin, Hydroxypropyl betadex, Hydroxypropyl-β-cyclodextrin) is a well-known sugar used in drug delivery, genetic vectors, environmental protection, and the treatment of Niemann-Pick disease type C1 (NPC1). It is an inhibitor of amyloid-β aggregation and widely used drug delivery vehicle to improve stability and bioavailability.	Technol Cancer Res Treat, 2021, 20:15330338211027916 Oncotarget, 2015, 6(30):29497-512
S3923	Ginsenoside Rg1	Ginsenoside Rg1 (Ginsenoside A2, Panaxoside A, Panaxoside Rg1, Sanchinoside C1, Sanchinoside Rg1), one of the major active components of ginseng, is identified as a protopanaxatriol-type and has pharmacological actions such as neuroprotective and anti-tumor effects on various cancer types. Ginsenoside Rg1 reduces cerebral Aβ levels and NF-κB nuclear translocation.	CNS Neurosci Ther, 2022, 10.1111/cns.14000 J Ethnopharmacol, 2021, S0378-8741(21)00169-0
S3811	Ginsenoside Re	Ginsenoside Re (Ginsenoside B2, Panaxoside Re, Sanchinoside Re, Chikusetsusaponin Ivc), an extract from Panax notoginseng, is a major ginsenoside in ginseng and belongs to 20(S)-protopanaxatriol group. It has diverse in vitro and in vivo effects, including vasorelaxant, antioxidant, antihyperlipidemic, and angiogenic actions. Ginsenoside Re decreases the β-amyloid protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB.	J Ethnopharmacol, 2021, S0378-8741(21)00169-0
S0486	Hoechst 34580	Hoechst 34580 (HOE 34580) is a cell-permeable blue fluorescent dye to stain DNA and nuclei. Hoechst 34580 is also a good candidate for treating the Alzheimer's disease by inhibiting amyloid beta (Aβ) formation with IC50 of 0.86 μM.	Front Nutr, 2022, 9:961182
A2813	Anti-Amyloid Beta (CSIRO anti-amyloid Beta scFv)	Anti-Amyloid Beta (CSIRO anti-amyloid Beta scFv) is a recombinant monoclonal antibody in a single chain fragment variable (scFv) against amyloid beta, has the potential to be used in Alzheimer's disease (AD) research. MW : 145.14 KD.
E2948	β-Amyloid (25-35)	β-Amyloid (25-35) (Amyloid beta-peptide (25-35), Aβ25-35, β-Amyloid peptide (25-35)) , a sequence GSNKGAIIGLM, is a highly toxic synthetic derivative of Amyloid beta-peptide (Aβ-peptides) which forms fibrillary aggregates. β-Amyloid (25-35) is involved in the pathogenesis of Alzheimer's disease.
A2833	Donanemab (Anti-Amyloid Beta)	Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research. MW : 145.36 KD.
S0529	PBD-150	PBD-150 is a potent human glutaminyl cyclase (hQC) Y115E-Y117E variant inhibitor with Ki of 60 nM.
A2933	Anti-Amyloid Beta (Merck anti-Amyloid beta 19.3)	Anti-Amyloid Beta (Merck anti-Amyloid beta 19.3) is a human monoclonal antibody targeting beta-amyloid with the potential to treat Alzheimer’s disease. MW: 145.22 KD.
S5101	Tabersonine hydrochloride	Tabersonine, an ingredient extracted from the bean of Voacanga africana, is a potent inhibitor against Aβ(1−42) aggregation and toxicity.
E0077	Simufilam	Simufilam(PTI-125) is a potent, orally active small drug against AD, which interacts to filamin and controls the actin cytoskeleton. Simufilam reduces tau hyperphosphorylation, amyloid and tau formation by preventing and reversing the binding of Aβ42 to α7nAChR.
S9087	Tenuifolin	Tenuifolin, a secondary saponin isolated from hydrolysates of polygalasaponins, inhibits beta-amyloid synthesis in vitro and has nootropic activity in vivo via acetylcholine esterase inhibition and increases norepinephrine and dopamine production.
S6733	Edonerpic maleate	Edonerpic maleate (T-817) is a novel neurotrophic agent which can inhibit amyloid-β peptides (Aβ).
S9428	Brazilin	Brazilin (Natural Red 24) is a red pigment obtained from the wood of the brazilwood family. It is used to dye fabric and has diverse biological activities, including neuroprotective, anti-inflammatory, antibacterial, and antioxidant properties.
S2418	Frentizole	Frentizole (Frentizol) is a novel inhibitor of amyloid beta peptide (Abeta) binding alcohol dehydrogenase (ABAD) interaction with IC50 of 200 μM. Frentizole is a nontoxic antiviral and immunosuppressive agent used clinically in rheumatoid arthritis and systemic lupus erythematosus.
S3405	CRANAD-2	CRANAD-2 is a curcumin-derivatized near-infrared (NIR) probe that meets all the requirements for a NIR contrast agent for the detection of Abeta plaques both in vitro and in vivo.
A2764	Crenezumab (Anti-Amyloid Beta)	Crenezumab (Anti-Amyloid Beta) is a fully humanized  immunoglobulin (Ig) G4 monoclonal antibody that targets amyloid beta (Abeta) with potential for use in Alzheimer's disease research. MW: 143.58 kD.
A2766	Gantenerumab (Anti-Amyloid Beta)	Gantenerumab (Anti-Amyloid Beta) is a fully human IgG1 monoclonal antibody against beta-amyloid (Abeta40/42) used in the treatment of Alzheimer's disease. MW: 146.28 kD.
A2767	GSK 933776 (Anti-Amyloid Beta)	GSK 933776 (Anti-Amyloid Beta) is a humanized monoclonal antibody against beta-amyloid used in the treatment of Alzheimer's disease. MW: 145.34 kD.
A2588	Aducanumab (Anti-Amyloid Beta)	Aducanumab (Anti-Amyloid Beta) is a selective human monoclonal antibody targeting aggregated forms of amyloid beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research.MW :145.5 KD.
A2589	Birtamimab (Anti-Amyloid Alpha)	Birtamimab(Anti-Amyloid Alpha) is an investigational monoclonal antibody that specifically and selectively targets and clear the amyloid. It can be used for treatment to remove amyloid from the vital organs, and research of light chain amyloidosis.MW :145.5 KD.
A2800	Anti-Amyloid Beta (CNTO 2125)	Anti-Amyloid Beta (CNTO 2125) is a human monoclonal antibody against amyloid beta has the potential to be used in Alzheimer's disease (AD) research. MW : 143.86 KD.
S2215	DAPT	DAPT (GSI-IX、LY-374973) は新規の γ-セクレターゼ 阻害剤であり、HEK 293 細胞で 20 nM の IC50 で Aβ 産生を阻害します。 DAPT はヒト舌癌細胞のアポトーシス(apoptosis) を促進し、オートファジー (autophagy) を調節します。	Nat Biotechnol, 2024, 10.1038/s41587-024-02386-x Nat Commun, 2024, 15(1):9529 J Clin Invest, 2024, 134(18)e179860
S1575	RO4929097	RO4929097 (RG-4733) is a γ secretase inhibitor with IC50 of 4 nM in a cell-free assay, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively. Phase 2.	J Cell Physiol, 2024, 10.1002/jcp.31291 Cell Transplant, 2024, 33:9636897241288932 Res Sq, 2024, rs.3.rs-3843028
S5742	Deferoxamine mesylate	Deferoxamine mesylate is the mesylate salt of Deferoxamine, which forms iron complexes and is used as a chelating agent. Deferoxamine is a ferroptosis inhibitor that stabilizes HIF-1α expression and improves HIF-1α transactivity in hypoxic and hyperglycemic states in vitro. Deferoxamine decreases beta-amyloid (Aβ) deposition and induces autophagy.Please do not prepare stock solutions with normal saline or PBS, as precipitation may occur.	Mol Cancer, 2024, 23(1):240 Cancer Commun (Lond), 2024, 10.1002/cac2.12608 Adv Sci (Weinh), 2024, 11(40):e2402671
S8185	FPS-ZM1	FPS-ZM1 is a blood-brain-barrier permeant, non-toxic, tertiary amide compound which is a high affinity RAGE-specific inhibitor, blocking Aβ binding to the V domain of RAGE.	Clin Immunol, 2024, 262:110178 Pharmacol Res, 2023, 192:106791 Cell Death Dis, 2023, 14(12):825
S1262	Avagacestat (BMS-708163)	Avagacestat (BMS-708163) is a potent, selective, orally bioavailable γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 of 0.3 nM and 0.27 nM, demonstrating a 193-fold selectivity against Notch. Phase 2.	Nat Commun, 2022, 13(1):6345 Sci Rep, 2022, 12(1):7 Cell, 2021, 184(2):521-533.e14
S2660	MK-0752	MK-0752 is a moderately potent γ-secretase inhibitor, which reduces Aβ40 production with IC50 of 5 nM. Phase 1/2.	Nat Cell Biol, 2024, 26(3):353-365 Cancers (Basel), 2023, 15(6)1883 J Cancer Res Clin Oncol, 2023, 149(16):14691-14699
S1594	Semagacestat (LY450139)	Semagacestat (LY450139) is a γ-secretase blocker for Aβ42, Aβ40 and Aβ38 with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, also inhibits Notch signaling with IC50 of 14.1 nM in H4 human glioma cell. Phase 3.	Cancers (Basel), 2023, 15(6)1883 Sci Rep, 2022, 12(1):7 Calcif Tissue Int, 2022, 111(2):211-223
S1528	LY2811376	LY2811376 is the first orally available non-peptidic β-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM, that act to decrease Aβ secretion with EC50 of 300 nM, demonstrated to have 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including cathepsin D, pepsin, or renin. Phase 1.	Glycobiology, 2023, 33(4):325-341 J Agric Food Chem, 2022, 70(5):1536-1546 Sci Rep, 2022, 12(1):7
S4261	EUK 134	EUK 134, a synthetic superoxide dismutase (SOD)/catalase mimetic, exhibits potent antioxidant activities, and inhibits the formation of β-amyloid and related amyloid fibril.	Front Aging Neurosci, 2022, 14:1013943 Chem Biol Interact, 2021, 351:109756 Nat Commun, 2020, 23;11(1):433
S9664	Colivelin	Colivelin (CLN) is a brain-penetrant neuroprotective peptide with potent long-term capacity against Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. Colivelin is an activator of STAT3.	Commun Biol, 2024, 7(1):999 Heliyon, 2024, 10(9):e30445 Research Square, 2024, 10.21203/rs.3.rs-3840462/v1
S4760	(2-Hydroxypropyl)-β-cyclodextrin (HP-β-CD)	(2-Hydroxypropyl)-β-cyclodextrin (HP-β-CD, HP-β-cyclodextrin, Hydroxypropyl betadex, Hydroxypropyl-β-cyclodextrin) is a well-known sugar used in drug delivery, genetic vectors, environmental protection, and the treatment of Niemann-Pick disease type C1 (NPC1). It is an inhibitor of amyloid-β aggregation and widely used drug delivery vehicle to improve stability and bioavailability.	Technol Cancer Res Treat, 2021, 20:15330338211027916 Oncotarget, 2015, 6(30):29497-512
S3923	Ginsenoside Rg1	Ginsenoside Rg1 (Ginsenoside A2, Panaxoside A, Panaxoside Rg1, Sanchinoside C1, Sanchinoside Rg1), one of the major active components of ginseng, is identified as a protopanaxatriol-type and has pharmacological actions such as neuroprotective and anti-tumor effects on various cancer types. Ginsenoside Rg1 reduces cerebral Aβ levels and NF-κB nuclear translocation.	CNS Neurosci Ther, 2022, 10.1111/cns.14000 J Ethnopharmacol, 2021, S0378-8741(21)00169-0
S3811	Ginsenoside Re	Ginsenoside Re (Ginsenoside B2, Panaxoside Re, Sanchinoside Re, Chikusetsusaponin Ivc), an extract from Panax notoginseng, is a major ginsenoside in ginseng and belongs to 20(S)-protopanaxatriol group. It has diverse in vitro and in vivo effects, including vasorelaxant, antioxidant, antihyperlipidemic, and angiogenic actions. Ginsenoside Re decreases the β-amyloid protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB.	J Ethnopharmacol, 2021, S0378-8741(21)00169-0
S0486	Hoechst 34580	Hoechst 34580 (HOE 34580) is a cell-permeable blue fluorescent dye to stain DNA and nuclei. Hoechst 34580 is also a good candidate for treating the Alzheimer's disease by inhibiting amyloid beta (Aβ) formation with IC50 of 0.86 μM.	Front Nutr, 2022, 9:961182
S0529	PBD-150	PBD-150 is a potent human glutaminyl cyclase (hQC) Y115E-Y117E variant inhibitor with Ki of 60 nM.
S5101	Tabersonine hydrochloride	Tabersonine, an ingredient extracted from the bean of Voacanga africana, is a potent inhibitor against Aβ(1−42) aggregation and toxicity.
E0077	Simufilam	Simufilam(PTI-125) is a potent, orally active small drug against AD, which interacts to filamin and controls the actin cytoskeleton. Simufilam reduces tau hyperphosphorylation, amyloid and tau formation by preventing and reversing the binding of Aβ42 to α7nAChR.
S9087	Tenuifolin	Tenuifolin, a secondary saponin isolated from hydrolysates of polygalasaponins, inhibits beta-amyloid synthesis in vitro and has nootropic activity in vivo via acetylcholine esterase inhibition and increases norepinephrine and dopamine production.
S6733	Edonerpic maleate	Edonerpic maleate (T-817) is a novel neurotrophic agent which can inhibit amyloid-β peptides (Aβ).
S2418	Frentizole	Frentizole (Frentizol) is a novel inhibitor of amyloid beta peptide (Abeta) binding alcohol dehydrogenase (ABAD) interaction with IC50 of 200 μM. Frentizole is a nontoxic antiviral and immunosuppressive agent used clinically in rheumatoid arthritis and systemic lupus erythematosus.
A2813	Anti-Amyloid Beta (CSIRO anti-amyloid Beta scFv)	Anti-Amyloid Beta (CSIRO anti-amyloid Beta scFv) is a recombinant monoclonal antibody in a single chain fragment variable (scFv) against amyloid beta, has the potential to be used in Alzheimer's disease (AD) research. MW : 145.14 KD.
A2833	Donanemab (Anti-Amyloid Beta)	Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research. MW : 145.36 KD.
A2933	Anti-Amyloid Beta (Merck anti-Amyloid beta 19.3)	Anti-Amyloid Beta (Merck anti-Amyloid beta 19.3) is a human monoclonal antibody targeting beta-amyloid with the potential to treat Alzheimer’s disease. MW: 145.22 KD.
A2764	Crenezumab (Anti-Amyloid Beta)	Crenezumab (Anti-Amyloid Beta) is a fully humanized  immunoglobulin (Ig) G4 monoclonal antibody that targets amyloid beta (Abeta) with potential for use in Alzheimer's disease research. MW: 143.58 kD.
A2766	Gantenerumab (Anti-Amyloid Beta)	Gantenerumab (Anti-Amyloid Beta) is a fully human IgG1 monoclonal antibody against beta-amyloid (Abeta40/42) used in the treatment of Alzheimer's disease. MW: 146.28 kD.
A2767	GSK 933776 (Anti-Amyloid Beta)	GSK 933776 (Anti-Amyloid Beta) is a humanized monoclonal antibody against beta-amyloid used in the treatment of Alzheimer's disease. MW: 145.34 kD.
A2588	Aducanumab (Anti-Amyloid Beta)	Aducanumab (Anti-Amyloid Beta) is a selective human monoclonal antibody targeting aggregated forms of amyloid beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research.MW :145.5 KD.
A2589	Birtamimab (Anti-Amyloid Alpha)	Birtamimab(Anti-Amyloid Alpha) is an investigational monoclonal antibody that specifically and selectively targets and clear the amyloid. It can be used for treatment to remove amyloid from the vital organs, and research of light chain amyloidosis.MW :145.5 KD.
A2800	Anti-Amyloid Beta (CNTO 2125)	Anti-Amyloid Beta (CNTO 2125) is a human monoclonal antibody against amyloid beta has the potential to be used in Alzheimer's disease (AD) research. MW : 143.86 KD.

Beta Amyloidシグナル伝達経路